Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Li Wang
LAB HEAD: Poulikos Poulikakos
PROVIDER: PXD023137 | Pride | 2022-02-16
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
20181004_JinJ_ctrl_1.raw | Raw | |||
20181004_JinJ_ctrl_1_20181005040704.raw | Raw | |||
20181004_JinJ_ctrl_2.raw | Raw | |||
20181004_JinJ_ctrl_2_20181005102542.raw | Raw | |||
20181011_JinJ_140_11.raw | Raw |
Items per page: 5 1 - 5 of 15 |
Wu Xuewei X Yang Xiaobao X Xiong Yan Y Li Ruitong R Ito Takahiro T Ahmed Tamer A TA Karoulia Zoi Z Adamopoulos Christos C Wang Hong H Wang Li L Xie Ling L Liu Jing J Ueberheide Beatrix B Aaronson Stuart A SA Chen Xian X Buchanan Sean G SG Sellers William R WR Jin Jian J Poulikakos Poulikos I PI
Nature cancer 20210301 4
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely on CDK4 function, and are exquisitely sensitive to CDK4/6i. In contrast, tumor cells expressing both CDK4 and CDK6 have increased reliance on CDK6 to ensure cell cycle progression. We discovered that CDK4/6i and CDK4/6 degraders potently bind and inhibit CDK6 selectively in tumors in which CDK6 is highly the ...[more]